The GLP-1 Capacity Squeeze
As demand for GLP-1 medicines grows, injectable manufacturers must increase output without compromising quality or squeezing supply for other therapies
By
Tommy Schornak
September 16, 2026
Clinical Scorecard: The GLP-1 Capacity Squeeze
At a Glance
Category Detail
Condition Type 2 Diabetes and Obesity Key Mechanisms Increase insulin and decrease glucagon secretion Target Population Patients with type 2 diabetes and obesity Care Setting Injectable treatments in various healthcare settings
Key Highlights
GLP-1 receptor agonists are increasingly used for type 2 diabetes and obesity. Projected increase in GLP-1 treatment users from 5 million in 2023 to 25 million by 2030. Manufacturing capacity for GLP-1s is under strain due to rising demand. Injectable formats must accommodate both patient-friendly and clinical administration needs. Regulatory changes necessitate enhanced contamination control strategies. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with type 2 diabetes and obesity requiring injectable therapies
Manufacturers must ensure quality and flexibility in production to meet diverse needs.
Clinical Best Practices
Invest in modular and flexible manufacturing capabilities. Maintain rigorous sterility and stability throughout drug handling. Adapt to regulatory changes with purpose-built facilities. Related Resources & Content
